John Fraser Wright

机构：Oxford BioMedica (United Kingdom) · ORCID：0000-0001-9635-1750

发表论文 116 篇 · 总被引 17973 次 · h-index 50

代表论文

• Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia (2013 · New England Journal of Medicine · 被引 3531)
• Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial (2017 · The Lancet · 被引 1968)
• Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant (2017 · New England Journal of Medicine · 被引 776)
• Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial (2016 · The Lancet · 被引 471)
• Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy (2019 · Ophthalmology · 被引 407)
• AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness (2012 · Science Translational Medicine · 被引 399)